Transgenic Mouse Model of Chronic Beryllium Disease
- NYU School of Medicine
Animal models provide powerful tools for dissecting dose-response relationships and pathogenic mechanisms and for testing new treatment paradigms. Mechanistic research on beryllium exposure-disease relationships is severely limited by a general inability to develop a sufficient chronic beryllium disease animal model. Discovery of the Human Leukocyte Antigen (HLA) - DPB1Glu69 genetic susceptibility component of chronic beryllium disease permitted the addition of this human beryllium antigen presentation molecule to an animal genome which may permit development of a better animal model for chronic beryllium disease. Using FVB/N inbred mice, Drs. Rubin and Zhu, successfully produced three strains of HLA-DPB1 Glu 69 transgenic mice. Each mouse strain contains a haplotype of the HLA-DPB1 Glu 69 gene that confers a different magnitude of odds ratio (OR) of risk for chronic beryllium disease: HLA-DPB1*0401 (OR = 0.2), HLA-DPB1*0201 (OR = 15), HLA-DPB1*1701 (OR = 240). In addition, Drs. Rubin and Zhu developed transgenic mice with the human CD4 gene to permit better transmission of signals between T cells and antigen presenting cells. This project has maintained the colonies of these transgenic mice and tested the functionality of the human transgenes.
- Research Organization:
- NYU School of Medicine
- Sponsoring Organization:
- USDOE Office of Science (SC)
- DOE Contract Number:
- FG02-04ER63919
- OSTI ID:
- 953218
- Report Number(s):
- DOE/RD832528
- Country of Publication:
- United States
- Language:
- English
Similar Records
Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients with primary Sjoegren's syndrome
Crystal structure of HLA-DP2 and implications for chronic beryllium disease